Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus

BACKGROUND: Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have demonstrated efficacy of dapagliflozin for type 2 diabetic patients in Korea. We evaluated the efficacy and safety o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Hyun A, Jung, Young Lee, Lee, Yong Hoon, Lee, Yu Chang, Lee, Jung Eun, Lee, Sol Jae, Jeong, Su Jin, Kim, Chong Hwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for the Study of Obesity 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484898/
https://www.ncbi.nlm.nih.gov/pubmed/31089504
http://dx.doi.org/10.7570/jomes.2017.26.2.107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484898/
https://www.ncbi.nlm.nih.gov/pubmed/31089504
http://dx.doi.org/10.7570/jomes.2017.26.2.107

Ejemplares similares